REFERENCES
- Gupta M, Davis M, LeGrand S, Walsh D, Lagman R. Nausea and vomiting in advanced cancer: the Cleveland Clinic protocol. J Support Oncol. 2013;11:8–13.
- Rojas C, Slusher BS. Pharmacological mechanisms of 5-HT(3) and tachykinin NK(1) receptor antagonism to prevent chemotherapy-induced nausea and vomiting. Eur J Pharmacol. 2012;684:1–7.
- Datta S, Williams N, Suortamo S, Carcinoid syndrome from small bowel endocrine carcinoma in the absence of hepatic metastasis. Age Ageing. 2011;40:760–762.
- Zinner MJ, Yeo CJ, Jaffe BM. The effect of carcinoid levels of serotonin and substance P on hemodynamics. Ann Surg. 1984;199:197–204.
- Prommer E. Aprepitant (EMEND): the role of substance P in nausea and vomiting. J Pain Palliat Care Pharmacother. 2005;19:31–39.
- Dos Santos LV, Souza FH, Brunetto AT, Sasse AD, da Silveira Nogueira Lima JP. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review. J Natl Cancer Inst. 2012;104:1280–1292.
- Gore RM, Mehta UK, Berlin JW, Rao V, Newmark GM. Diagnosis and staging of small bowel tumors. Cancer Imaging. 2006;6:209–212.